SGLT2抑制剂对糖尿病患者骨折、截肢的影响

Effect of SGLT2 Inhibitor on Fracture and Amputation of Diabetic Patients

钠葡萄糖协同转运蛋白2(SGLT2)抑制剂是一种新型口服降血糖药物,其降糖机制是抑制SGLT2,减少葡萄糖的重吸收。研究发现,SGLT2抑制剂可能导致骨折、截肢风险增加。本文主要对SGLT2抑制剂对糖尿病患者骨代谢、骨密度、骨折、截肢的影响及其影响因素进行综述,旨在为高危患者的临床用药提供参考。

Sodium-glucose cotransporter 2(SGLT2)inhibitor is a new type of oral hypoglycemic drug,its hypoglycemic mechanism is to inhibit SGLT2 and reduce glucose re-absorption.It has been reported that SGLT2 inhibitor may increase the risk of fracture and amputation.The present paper seeks to summarize relevantresearch on the effects and possible influencing factors of SGLT2 inhibitor on bone metabolism,bone mineral density,fracture and amputation in patients with diabetes mellitus,toprovide reference for clinical medication of high-risk patients.